We'd like your feedback
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.
Aran
Singanayagam
a.singanayagam@imperial.ac.uk
Dr
Anand
Shah
A.Shah2@rbht.nhs.uk
Aran
Singanayagam
a.singanayagam@imperial.ac.uk
Acute upper respiratory infectionsChronic lower respiratory diseases
This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.
Bronchiectasis is a chronic lung condition characterised by progressive susceptibility to symptomatic flare-ups (exacerbations). These episodes are a major cause of morbidity and mortality with limited treatment options. Historically, bacteria have been deemed responsible for most exacerbations leading to widespread treatment with prolonged antibiotics, however, there is increasing antimicrobial resistance and we urgently need new approaches.
We have recently found that, contrary to previous belief, a significant proportion of exacerbations (~40%) are associated with detection of viruses (most commonly rhinovirus) which may be an unrecognised trigger for bronchiectasis exacerbations. It remains unclear however whether viruses can directly trigger exacerbations in bronchiectasis and the mechanisms that predispose individuals to viral infections are unknown.
This project asks the following questions:
1. Does deliberately infecting bronchiectasis subjects with rhinovirus lead to development of an exacerbation?
2. Does bronchiectasis reduce the immune system's ability to respond to and fight off viral infection?
3. What are the changes that occur in the lungs during a viral infection that lead to bronchiectasis exacerbation?
In this study, we will administer rhinovirus into the nose of 36 subjects with bronchiectasis and 18 healthy control subjects to induce infection and record respiratory symptoms and lung function daily to determine whether rhinovirus infection causes greater symptoms in bronchiectasis compared to healthy individuals. We will take samples from the nose and also mucus coughed up by these individuals to analyse the antiviral immune response. We will additionally take cells from the lungs of these individuals using bronchoscopy (where a telescope is inserted into the airways). We will culture these cells in the laboratory and infect them with rhinovirus before again measuring how much interferon and other substances they produce. This will determine if bronchiectasis is associated with a reduced ability of the immune system to respond to a viral infection.
Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.
The recruitment start and end dates are as follows:
Type: Active Monitoring;
You can take part if:
You may not be able to take part if:
For healthy volunteers: 1) Any significant medical co-morbidity 2) current smoking history within last 12 months or ex smoking history > 5 pack years For bronchiectasis study subjects our exclusion criteria will be: 1) Current smokers within last 12 months 2) Individuals with Bronchiectasis secondary to cystic fibrosis, primary immunodeficiency, primary ciliary dyskinesia and allergic bronchopulmonary aspergillosis 3) Individuals with other concomitant chronic lung disease diagnoses (e.g. COPD, asthma, interstitial lung disease) 4) FEV1 < 50% predicted 5) Pre-existing serum neutralising antibodies to RV-A16 (strain to be used for challenge) 6) Close contact with infants or elderly individuals either at home or workplace 7) Pregnancy or breastfeeding 8) Recent antibiotics for exacerbations within the preceding 12 weeks and prophylactic antibiotics (azithromycin or nebulised antibiotics) within preceding 4 weeks 9) Corticosteroid use (inhaled, nasal or systemic) within preceding 4 weeks.
Below are the locations for where you can take part in the trial. Please note that not all sites may be open.
Dr
Anand
Shah
A.Shah2@rbht.nhs.uk
Aran
Singanayagam
a.singanayagam@imperial.ac.uk
Aran
Singanayagam
a.singanayagam@imperial.ac.uk
The study is sponsored by Imperial College of Science, Technology and Medicine and funded by Medical Research Council (MRC) .
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Read full details
for Trial ID: CPMS 58921
You can print or share the study information with your GP/healthcare provider or contact the research team directly.
